Table 2 Posterior probability of non-inferiority for FF/VI versus other relevant ICS/LABA combination therapies*
A | |||||
Treatment (mcg) | Comparator (mcg) | Mean difference, l (95 % CrI) | Probability of non-inferiority Margin (l/min) | ||
12 | 15 | ||||
FF/VI 92/22 | FP/SAL 250/50 | 2.832 (−12.867–18.531) | 97 % | 99 % | |
FF/VI 92/22 | BUD/FORM 320/9 | 0.579 (−15.155–16.312) | 94 % | 98 % | |
FF/VI 184/22 | FP/SAL 500/50 | 11.323 (0.289–22.357) | >99 % | >99 % | |
FF/VI 184/22 | BUD/FORM 640/18 | 15.136 (−0.943–31.215) | >99 % | >99 % | |
B | |||||
Treatment | Comparator | Mean difference, ml (95 % CrI) | Probability of non-inferiority Margin (ml) | ||
75 | 100 | 125 | |||
FF/VI 92/22 | FP/SAL 250/50 | −36 (−92–19) | 92 % | 99 % | >99 % |
FF/VI 92/22 | BUD/FORM 320/9 | −27 (−98–45) | 91 % | 98 % | >99 % |
FF/VI 184/22 | FP/SAL 500/50 | 147 (48–247) | >99 % | >99 % | >99 % |
FF/VI 184/22 | BUD/FORM 640/18 | 118 (−19–255) | >99 % | >99 % | >99 % |
C | |||||
Treatment | Comparator | Rate ratio (95 % CrI) | Probability of non-inferiority Margin (event rate ratio) | ||
10 % | 20 % | ||||
FF/VI 92/22 | FP/SAL 250/50 | 1.164 (0.428–3.333) | 74 % | 78 % | |
FF/VI 92/22 | BUD/FORM 320/9 | 0.985 (0.336–2.574) | 82 % | 86 % | |
D | |||||
Treatment | Comparator | Mean difference, units (95 % CrI) | Probability of non-inferiority Margin (units) | ||
0.25 | 0.5 | ||||
FF/VI 92/22 | FP/SAL 250/50 | 0.060 (−0.104–0.224) | >99 % | >99 % | |
FF/VI 92/22 | BUD/FORM 320/9 | 0.203 (−0.461–0.867) | 90 % | 96 % | |